Mirum Pharmaceuticals (MIRM) Provides Development Program Updates

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/11/2026


Go back to Mirum Pharmaceuticals (MIRM) Provides Development Program Updates

Citi Reiterates Buy Rating on Mirum (MIRM), PT $34, 'Volixibat ICP Trial Discontinued, PSC and PBC Readouts Remain On Track'

November 29, 2022 9:05 AM UTC

Citi analyst David Lebowitz reiterated a Buy rating and $34.00 price target on Mirum Pharamceuticals (NASDAQ: MIRM)

The analyst comments "Today, Mirum announced the discontinuation of Phase IIb OHANA study of volixibat in intrahepatic cholestasis of pregnancy (ICP) due to challenges in... More